Company intelligence / Profile preview
NFL Biosciences
Castelnau-le-Lez, Occitanie, Francenflbiosciences.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Other
01
Overview
NFL Biosciences’ lead candidate, NFL‑101—a nicotine-free tobacco leaf protein extract for smoking cessation—is in Phase 2b/Phase III clinical trials. Early results and ongoing studies aim to demonstrate efficacy as a botanical alternative for nicotine withdrawal. Additional pipeline programs target cannabis and alcohol addictions at the preclinical stage
- Therapeutic areas
- Psychiatry
- Modalities
- Botanical drugs (plant-derived extracts)natural products
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed yet; company aims to partner with pharma companies for commercialization in the future
Beyond the preview
Go deeper on NFL Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFL Biosciences.